Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 327-336

  Anis, Aslam H ^a,b,c   Hogg, Robert S ^b,c   Yip, Benita ^c   Wang, Xiao Hua ^a,b   Montaner, Julio S G ^a,b,c   O'Shauglinessy, Michael V ^a,b,c   Schechter, Martin T ^a,b,c  

^a Canadian HIV Trials Network   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; COST BENEFIT ANALYSIS; DRUG COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; PHARMACOECONOMICS; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BRITISH COLUMBIA; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 0031916173     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00007     Document Type: Article

References (23)

1. Bloom DE, Carliner G. The economic impact of AIDS in the United States. Science 1988; 239: 604-9
2. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102: 5-17
3. Scitovsky AA. Studying the cost of HIV-related illnesses: reflections on the moving target. Milbank Q 1989; 67: 318-44
4. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986; 256: 3103-16
5. Hellinger FJ. The life time costs of treating a person with HIV. JAMA 1993; 270: 474-8
6. Hardy A, Rauch K, Echenberg D, et al. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986; 255: 209-11
7. Simpson KN. Design and assessment ot cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 4: 528-32
8. Tolley K, Gyldmak M. The trealmenl and care costs of people with HIV infection or AIDS: development of a standardized cost framework for Europe. Health Policy 1993; 24: 55-70
9. Seage GR, Landers S, Lamh GA, et al. Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health 1990; 8: 835-9.
10. Schulman KA, Lynn LA, Glick HA, et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114 (9): 798-802
11. Chancellor JV, Hill AM, Sabin A, et al. Modeling the cost effectiveness lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997: 12 (1): 54-66
12. Petrou S. Current controversies in the treatment of HIV infection and AIDS. Pharmacoeconomics 1996; 10 (2): 105-8
13. Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Vancouver: British Columbia Centre for Excellence m HIV/AIDS, 1995
14. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemol Rec 1990; 65: 221-8
15. Patented Medicines Prices Review Board. Bulletin no: 14-9, schedule 4: CPI adjustment methodology. Ottawa: Patented Medicines Prices Review Board, 1994
16. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993; 14: 43-68
17. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation. Biometrics 1988; 44 (4): 1049-60
18. Moore RD, Chaisson RE. Costs to medicaid of advancing immunosuppression in an urban HIV-infected population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 223-31
19. Moore RD, Barrtlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10 (2): 109-13
20. Zucconi SL, Jacobson LP, Schrager LK, et al. Impact of immunosuppression on health care use by men in the multicenter AIDS cohort study (MACS). J Acquir Immune Deffic Syndr Hum Retrovirol 1994; 7: 607-16
21. Gable CB, Tierce JC, Simison D, et al. Cost of HIV+/AIDS at CD4 counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:413-20
22. Hurley SF, Kaldor JM, Carlin JB, et al. The usage and costs of health services for HIV infection in Australia. AIDS 1995; 9: 777-85
23. Pauly MV. The economics of moral hazard. Am Econ Rev 1968; 58 (3): 231-7